Publication | Open Access

Targeting of the WT191–138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination

VaccinationHuman Dendritic CellsCancer ImmunosurveillanceImmunologyImmune RegulationTherapeutic VaccineT Cell ImmunityCd4 T Cell ResponsesWt191–138 FragmentWt1-based VaccinationDendritic Cell BiologyCellular Immune ResponseMedicineCell Biology